PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.\', \'All of Us Research Program, National Institutes of Health, Bethesda, Maryland, USA.\', \'National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.\', \'Department of Medicine, School of Medicine, University of California, Irvine, Irvine, California, USA.\', \'National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.\', \'Vanderbilt University Medical Center, Nashville, Tennessee, USA.\', \'Harvard Medical School, Brigham and Women\'s Hospital, Boston, Massachusetts, USA.\', \'Centers for Disease Control and Prevention, Atlanta, Georgia, USA.\', \'Mayo Clinic, Rochester, Minnesota, USA.\', \'Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.\', \'School of Medicine, University of California, San Diego, San Diego, California, USA.\', \'National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.\', \'Columbia University Medical Center, New York, New York, USA.\', \'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/cid/ciab519
?:doi
?:hasPublicationType
?:journal
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
is ?:pmid of
?:pmid
?:pmid
  • 34128970
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all